- Investing Ideas
- /
- German Biotech Breakthroughs
German Biotech Breakthroughs
UPDATED Nov 30, 2023
Companys with strong funding and high growth potential
67 companies
| Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | Industry | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| FYBFormycon | €65.10 | 5.7% | -21.1% | €1.1b | €105.31 | PS15.4x | E80.4% | n/a | Pharmaceuticals & Biotech | ||
| 22ZZealand Pharma | kr.43.28 | -1.4% | 61.1% | kr.19.6b | kr.45.99 | PS57.1x | E39.8% | n/a | Pharmaceuticals & Biotech | ||
| 49BABeiGene | US$169.00 | -0.6% | -9.6% | US$19.1b | US$257.82 | PS8.8x | E56.5% | n/a | Pharmaceuticals & Biotech | ||
| IKAPAurinia Pharmaceuticals | US$7.85 | -4.2% | 64.4% | US$1.2b | US$12.01 | PS7.8x | E70.8% | n/a | Pharmaceuticals & Biotech | ||
| 41XArdelyx | US$3.94 | 1.0% | 143.9% | US$1.0b | US$8.42 | PS7.8x | E72.3% | n/a | Pharmaceuticals & Biotech | ||
| 1AEargenx | €404.70 | -9.5% | 5.2% | €24.1b | €515.78 | PS25.5x | E71.4% | n/a | Pharmaceuticals & Biotech | ||
| 12X1Anavex Life Sciences | US$6.52 | 6.4% | -23.2% | US$582.0m | US$42.47 | PB4.2x | E89.8% | n/a | Pharmaceuticals & Biotech | ||
| 6IBInnovent Biologics | HK$5.10 | 2.8% | 45.7% | HK$74.0b | HK$6.25 | PS13.5x | E61.1% | n/a | Pharmaceuticals & Biotech | ||
| OL0Devyser Diagnostics | kr6.26 | 13.8% | 4.7% | kr1.2b | kr9.65 | PS7.6x | E121.0% | n/a | Pharmaceuticals & Biotech | ||
| IMUImmunoGen | US$26.91 | 83.2% | 449.6% | US$4.3b | US$42.54 | PS14.9x | E59.7% | n/a | Pharmaceuticals & Biotech | ||
| UXI4Cyclacel Pharmaceuticals | US$0.25 | 27.3% | -67.0% | US$3.8m | US$11.57 | PS9.8x | E33.2% | n/a | Pharmaceuticals & Biotech | ||
| 3EE0Kancera | kr0.39 | 32.0% | 133.2% | kr378.2m | n/a | PB5.7x | E120.5% | n/a | Pharmaceuticals & Biotech | ||
| 7AY1Actinium Pharmaceuticals | US$3.78 | -5.5% | -63.8% | US$114.6m | US$14.65 | PB2.9x | E74.5% | n/a | Pharmaceuticals & Biotech | ||
| LWBAMesoblast | AU$1.24 | 2.5% | -64.2% | AU$329.5m | AU$2.11 | PS29x | E58.5% | n/a | Pharmaceuticals & Biotech | ||
| 49BBeiGene | US$12.80 | -0.8% | -7.9% | US$19.1b | US$19.53 | PS8.8x | E56.5% | n/a | Pharmaceuticals & Biotech | ||
| 9IIBiovica International | kr0.20 | -9.1% | -80.3% | kr118.9m | kr2.01 | PS16.6x | E79.4% | n/a | Pharmaceuticals & Biotech | ||
| 6XPXspray Pharma | kr5.00 | 0% | n/a | kr1.4b | n/a | PB2.8x | E124.4% | n/a | Pharmaceuticals & Biotech | ||
| P7N1Sierra Oncology | €52.00 | 0% | 217.1% | €1.3b | n/a | PB4.9x | E64.3% | n/a | Pharmaceuticals & Biotech | ||
| VPA1AVEO Pharmaceuticals | US$13.77 | 0.7% | 358.7% | US$521.4m | US$13.77 | PS5.5x | E123.0% | n/a | Pharmaceuticals & Biotech | ||
| 4KBKrystal Biotech | US$92.50 | 0% | n/a | US$2.8b | US$140.18 | PS331.1x | E67.8% | n/a | Pharmaceuticals & Biotech | ||
| 7UMUltimovacs | kr9.52 | -1.9% | -4.1% | kr3.9b | kr14.91 | PB11.3x | E51.2% | n/a | Pharmaceuticals & Biotech | ||
| YP1BImmutep | AU$0.17 | 0.6% | -24.9% | AU$350.7m | n/a | PS100x | E57.0% | n/a | Pharmaceuticals & Biotech | ||
| 1JKApellis Pharmaceuticals | US$49.60 | 16.4% | 7.2% | US$6.0b | US$70.20 | PS21.8x | E71.7% | n/a | Pharmaceuticals & Biotech | ||
| PCJAbeona Therapeutics | US$4.37 | 17.8% | 16.3% | US$121.4m | US$19.36 | PS33.3x | E64.5% | n/a | Pharmaceuticals & Biotech |